Fulgent Genetics Stock

Fulgent Genetics ROE

The Return on Equity (ROE) of Fulgent Genetics (FLGT) as of Aug 15, 2026 is -5.44 %. In the previous year, Return on Equity (ROE) was -3.77 % — a change of 44.40% (lower).

ROE

-5.44 %

YoY

44.40%

Last updated:

In 2026, Fulgent Genetics's return on equity (ROE) was -5.44 %, a 44.40% increase from the -3.77 % ROE in the previous year.

Access this data via the Eulerpool API

Fulgent Genetics Stock analysis

What does Fulgent Genetics do? Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world. Fulgent Genetics is one of the most popular companies on Eulerpool.

ROE Details

Decoding Fulgent Genetics's Return on Equity (ROE)

Fulgent Genetics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Fulgent Genetics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Fulgent Genetics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Fulgent Genetics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Fulgent Genetics stock

Return on Equity (ROE) of Fulgent Genetics is -5.44 % in 2026.

Return on Equity (ROE) of Fulgent Genetics changed from -3.77 % to -5.44 %, representing a 44.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Fulgent Genetics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Fulgent Genetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Fulgent Genetics

All Key Metrics — Fulgent Genetics